Lyra Therapeutics (LYRA) Other Working Capital Changes (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Other Working Capital Changes of -$7000.0 in Q4 2025, up 72.0% on a QoQ basis from -$25000.0 in Q3 2025, and up 99.66% YoY from -$3506.0 in Q4 2024.
Lyra Therapeutics (LYRA) Other Working Capital Changes (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Other Working Capital Changes for 7 consecutive years, with -$7000.0 the latest figure, recorded in Q4 2025.
- Other Working Capital Changes for Q4 2025 came in at -$7000.0, up 99.66% year-over-year; the trailing twelve-month figure through Dec 2025 was -$398000.0 (up 88.23% YoY), and the FY2025 annual result was -$398000.0, up 88.23% from the prior year.
- Other Working Capital Changes for Q4 2025 stood at -$7000.0, up from -$25000.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $2.4 million in Q1 2023, with the low at -$4.1 million in Q4 2023.
- A 5-year average of -$74100.0 and a median of -$216000.0 in 2021 frame the typical range for Other Working Capital Changes.
- Across the five-year window, Other Working Capital Changes soared 5441.63% in 2021 and sank 3090.91% in 2023, its largest moves.
- Lyra Therapeutics' Other Working Capital Changes stood at $12.4 million in 2021, then plunged by 100.09% to -$11000.0 in 2022, then slumped by 3090.91% to -$351000.0 in 2023, then slumped by 485.75% to -$2.1 million in 2024, then surged by 99.66% to -$7000.0 in 2025.
- The last three Other Working Capital Changes figures came in at -$7000.0 (Q4 2025), -$25000.0 (Q3 2025), and -$183000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Sep 30, 2025 | -25,000.00 |
| Sep 30, 2025 | -25,000.00 |
| Sep 30, 2025 | -25,000.00 |
| Jun 30, 2025 | -183,000.00 |
| Jun 30, 2025 | -183,000.00 |
| Jun 30, 2025 | -183,000.00 |
| Mar 31, 2025 | -183,000.00 |
| Mar 31, 2025 | -183,000.00 |
| Mar 31, 2025 | -183,000.00 |
| Dec 31, 2024 | -2.06 Mn |
| Dec 31, 2024 | -2.06 Mn |
| Dec 31, 2024 | -2.06 Mn |
| Sep 30, 2024 | -195,000.00 |
| Sep 30, 2024 | -195,000.00 |
| Sep 30, 2024 | -195,000.00 |
| Jun 30, 2024 | -540,000.00 |
| Jun 30, 2024 | -540,000.00 |